Waldenström macroglobulinemia: What a hematologist needs to know

Prashant Kapoor, Jonas Paludo, Nishanth Vallumsetla, Philip R. Greipp

Research output: Contribution to journalArticlepeer-review

27 Scopus citations


Waldenström macroglobulinemia (WM) is a distinct hematologic malignancy characterized by a lymphoplasmacytic bone marrow infiltration and the presence of immunoglobulin (Ig)M monoclonal protein. Patients typically present at an advanced age, and a substantial proportion are asymptomatic at diagnosis. A unifying diagnosis of WM may be missed by an unsuspecting hematologist, as symptomatic patients present with a multitude of non-specific manifestations. Although constitutional and neuropathy-related symptoms predominate, concomitant IgM-induced hyperviscosity-associated features can provide useful diagnostic clues. There are specific indications for initiation of therapy. This review focuses on the most up-to-date management strategies of WM, in addition to highlighting the recent discoveries of MYD88 and CXCR4 mutations that have shed unprecedented light on the complex signaling pathways, and opened avenues for novel therapeutic targeting. Although WM remains incurable, with the rapid emergence and integration of effective novel therapies, its clinical course appears poised to improve in the foreseeable future.

Original languageEnglish (US)
Pages (from-to)301-319
Number of pages19
JournalBlood Reviews
Issue number5
StatePublished - Sep 1 2015


  • IgM monoclonal gammopathy
  • Indolent lymphoma
  • Lymphoplasmacytic lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Waldenström macroglobulinemia: What a hematologist needs to know'. Together they form a unique fingerprint.

Cite this